Chem2Side: A Deep Learning Model with Ensemble Augmentation (Conventional + Pix2Pix) for COVID-19 Drug Side-Effects Prediction from Chemical Images

Author:

Arshed Muhammad Asad1ORCID,Ibrahim Muhammad1ORCID,Mumtaz Shahzad2ORCID,Tanveer Muhammad3,Ahmed Saeed4ORCID

Affiliation:

1. Department of Computer Science, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan

2. Department of Data Science, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan

3. School of Systems and Technology, University of Management and Technology, Lahore 54770, Pakistan

4. Department of Experimental Medical Science, Biomedical Center (BMC), Lund University, 22184 Lund, Sweden

Abstract

Drug side effects (DSEs) or adverse drug reactions (ADRs) are a major concern in the healthcare industry, accounting for a significant number of annual deaths in Europe alone. Identifying and predicting DSEs early in the drug development process is crucial to mitigate their impact on public health and reduce the time and costs associated with drug development. Objective: In this study, our primary objective is to predict multiple drug side effects using 2D chemical structures, especially for COVID-19, departing from the conventional approach of relying on 1D chemical structures. We aim to develop a novel model for DSE prediction that leverages the CNN-based transfer learning architecture of ResNet152V2. Motivation: The motivation behind this research stems from the need to enhance the efficiency and accuracy of DSE prediction, enabling the pharmaceutical industry to identify potential drug candidates with fewer adverse effects. By utilizing 2D chemical structures and employing data augmentation techniques, we seek to revolutionize the field of drug side-effect prediction. Novelty: This study introduces several novel aspects. The proposed study is the first of its kind to use 2D chemical structures for predicting drug side effects, departing from the conventional 1D approaches. Secondly, we employ data augmentation with both conventional and diffusion-based models (Pix2Pix), a unique strategy in the field. These innovations set the stage for a more advanced and accurate approach to DSE prediction. Results: Our proposed model, named CHEM2SIDE, achieved an impressive average training accuracy of 0.78. Moreover, the average validation and test accuracy, precision, and recall were all at 0.73. When evaluated for COVID-19 drugs, our model exhibited an accuracy of 0.72, a precision of 0.79, a recall of 0.72, and an F1 score of 0.73. Comparative assessments against established transfer learning and machine learning models (VGG16, MobileNetV2, DenseNet121, and KNN) showcased the exceptional performance of CHEM2SIDE, marking a significant advancement in drug side-effect prediction. Conclusions: Our study introduces a groundbreaking approach to predicting drug side effects by using 2D chemical structures and incorporating data augmentation. The CHEM2SIDE model demonstrates remarkable accuracy and outperforms existing models, offering a promising solution to the challenges posed by DSEs in drug development. This research holds great potential for improving drug safety and reducing the associated time and costs.

Publisher

MDPI AG

Subject

Information Systems

Reference40 articles.

1. Adverse drug reactions in primary care: A scoping review;Khalil;BMC Health Serv. Res.,2020

2. Druggable Targets and Targeted Drugs: Enhancing the Development of New Therapeutics;Billingsley;Pharmacology,2008

3. When good drugs go bad;Giacomini;Nature,2007

4. (2023, April 10). Drugs|FDA, Available online: https://www.fda.gov/drugs.

5. Safety Monitoring in Clinical Trials;Yao;Pharmaceutics,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3